Vaccine Market Size, Share & Trends Analysis Report By Indication, By Type, By Route Of Administration, By Age Group, By Distribution Channel, By Region, And Segment Forecasts, 2026

The global vaccine market size was estimated at USD 72.75 billion in 2025 and is projected to reach USD 115.77 billion by 2033, growing at a CAGR of 5.78% from 2026 to 2033. The market is driven by the increasing investment in R&D and the rising focus of sponsors & investigators on reducing research costs.

Moreover, the increasing adoption of outsourcing laboratory services by pharmaceutical & biotechnology companies and other end users to reduce the overall cost of research activities further supports the market growth over the forecast period. The global vaccine industry is positioned as a strategic component of preventive healthcare systems and is primarily driven by public immunization programs, outbreak preparedness, and routine disease prevention initiatives across regions. Vaccines are integrated into national healthcare budgets and long-term public health planning due to their role in reducing disease burden and downstream treatment costs. According to the World Health Organization, immunization prevents an estimated 2-3 million deaths every year worldwide by protecting against vaccine-preventable diseases such as measles, diphtheria, tetanus, pertussis, and influenza. In April 2024, the WHO published a comprehensive analysis in The Lancet reporting that global immunization programs have prevented approximately 154 million deaths over the past 50 years, reinforcing vaccination as a central public health investment. In April 2025, the World Health Organization marked World Immunization Week with a focus on closing immunization gaps, strengthening immunization delivery systems, and expanding vaccine coverage across the life course, reflecting continued global policy prioritization of immunization as a core public health intervention.

Market growth is supported by the continued prevalence of infectious diseases, expansion of adult and geriatric immunization programs, and recovery of routine vaccination coverage following pandemic-related disruptions. According to the World Health Organization Global Tuberculosis Report 2024, an estimated 10.8 million people developed tuberculosis globally in 2023, with the highest burden concentrated in regions such as Southeast Asia and Africa, sustaining demand for preventive and control strategies in high-burden markets. In April 2024, the World Health Organization Global Hepatitis Report estimated that approximately 254 million people were living with chronic hepatitis B and 50 million with chronic hepatitis C worldwide, with more than 1 million new viral hepatitis infections occurring each year, underscoring the continued public health burden of hepatitis globally. In May 2025, the U.S. Food and Drug Administration approved Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, for older adults aged 65 years and above and for individuals aged 12-64 years with underlying medical conditions, indicating continued regulatory support for vaccine adoption among high-risk populations.

The market is increasingly shaped by shifts in technology platforms, product portfolios, and manufacturing strategies, reflecting a transition toward broader disease coverage and long-term supply resilience. Platform-based development approaches, particularly mRNA technologies, have enabled faster design cycles, greater flexibility in antigen selection, and the development of combination vaccines, supporting portfolio expansion beyond single-disease products. These advancements are contributing to increased focus on respiratory indications and multi-pathogen prevention strategies, particularly within adult and elderly populations. In September 2022, Pfizer and BioNTech initiated Phase III clinical trials for an mRNA-based influenza vaccine, marking the extension of mRNA platforms beyond COVID-19 applications. In May 2025, the World Health Organization reported that its mRNA Technology Transfer Programme had expanded to 15 global partners, supporting the decentralization of vaccine manufacturing and the development of regional production capacity. In parallel, expanding adult immunization frameworks and broader regulatory recommendations are increasing the addressable market for vaccines across age groups, indicating that market evolution is being driven by public-sector priorities, platform diversification, and demographic shifts rather than short-term demand fluctuations.

Global Vaccine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global vaccine market report based on indication, type, route of administration, age group, distribution channel, and region:

Indication Outlook (Revenue, USD Million, 2021 - 2033)
Viral Vaccines
- Hepatitis
- Pediatric (Children)
- Adult
- Influenza
- Pediatric (Children)
- Adult
- HPV
- Pediatric (Children)
- Adult
- MMR
- Pediatric (Children)
- Adult
- Rotavirus
- Pediatric (Children)
- Adult
- Herpes Zoster
- Pediatric (Children)
- Adult
- Japanese Encephalitis
- Pediatric (Children)
- Adult
- RSV
- Pediatric (Children)
- Adult
- Others
- Pediatric (Children)
- Adult
Bacterial Vaccines
- Meningococcal Diseases
- Pediatric (Children)
- Adult
- Pneumococcal diseases
- Pediatric (Children)
- Adult
- DPT
- Pediatric (Children)
- Adult
- Others
- Pediatric (Children)
- Adult
Cancer Vaccines
- Pediatric (Children)
- Adult
Allergy Vaccines
- Pediatric (Children)
- Adult
Other
- Pediatric (Children)
- Adult
Type Outlook (Revenue, USD Million, 2021 - 2033)
Subunit Vaccines
- Recombinant Vaccines
- Conjugate Vaccines
- Toxoid Vaccines
Inactivated
Live Attenuated
mRNA Vaccines
Viral Vector Vaccines
Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
Oral
Parenteral
Nasal
Age Group Outlook (Revenue, USD Million, 2021 - 2033)
Pediatric
Adult
Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
Hospital & Retail Pharmacies
Government Suppliers
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Product Code: 978-1-68038-990-6

Chapter 1. Methodology and Scope

1.1 Market Segmentation & Scope
1.2 Segment Definitions
- 1.2.1 Indication
- 1.2.2 Type
- 1.2.3 Route of Administration
- 1.2.4 Age Group
- 1.2.5 Distribution Channel
1.3 Estimates and Forecast Timeline
1.4 Research Methodology
1.5 Information Procurement
- 1.5.1 Purchased Database
- 1.5.2 GVR's Internal Database
- 1.5.3 Secondary Sources
- 1.5.4 Primary Research
1.6 Information Analysis
- 1.6.1 Data Analysis Models
1.7 Market Formulation & Data Visualization
1.8 Model Details
- 1.8.1 Commodity Flow Analysis
1.9 List of Secondary Sources
1.10 Objectives

Chapter 2. Executive Summary

2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot

Chapter 3. Vaccine Market Variables, Trends, & Scope

3.1 Market Lineage Outlook
3.2 Market Dynamics
- 3.2.1 Market Driver Analysis
- 3.2.2 Market Restraint Analysis
3.3 Business Environment Analysis
- 3.3.1 Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1 Supplier Power
  - 3.3.1.2 Buyer Power
  - 3.3.1.3 Substitution Threat
  - 3.3.1.4 Threat of New Entrants
  - 3.3.1.5 Competitive Rivalry
- 3.3.2 PESTLE Analysis
- 3.3.3 Pipeline Analysis
- 3.3.4 Patent Expiry Analysis
- 3.3.5 Pricing Analysis

Chapter 4. Vaccine Market: Indication Business Analysis

4.1. Indication Market Share, 2025 & 2033
4.2. Indication Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
4.4. Viral Vaccines
- 4.4.1 Viral Vaccine Market, 2021 - 2033 (USD Million)
  - 4.4.1.1 Hepatitis Market, 2021 - 2033 (USD Million)
    - 4.4.1.1.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
    - 4.4.1.1.2 Adult Market, 2021 - 2033 (USD Million)
  - 4.4.1.2 Influenza Market, 2021 - 2033 (USD Million)
    - 4.4.1.2.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
    - 4.4.1.2.2 Adult Market, 2021 - 2033 (USD Million)
  - 4.4.1.3 HPV Market, 2021 - 2033 (USD Million)
    - 4.4.1.3.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
    - 4.4.1.3.2 Adult Market, 2021 - 2033 (USD Million)
  - 4.4.1.4 MMR Market, 2021 - 2033 (USD Million)
    - 4.4.1.4.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
    - 4.4.1.4.2 Adult Market, 2021 - 2033 (USD Million)
  - 4.4.1.5 Rotavirus Market, 2021 - 2033 (USD Million)
    - 4.4.1.5.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
    - 4.4.1.5.2 Adult Market, 2021 - 2033 (USD Million)
  - 4.4.1.6 Herpes Zoster Market, 2021 - 2033 (USD Million)
    - 4.4.1.6.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
    - 4.4.1.6.2 Adult Market, 2021 - 2033 (USD Million)
  - 4.4.1.7 Japanese Encephalitis Market, 2021 - 2033 (USD Million)
    - 4.4.1.7.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
    - 4.4.1.7.2 Adult Market, 2021 - 2033 (USD Million)
  - 4.4.1.8 RSV Market, 2021 - 2033 (USD Million)
    - 4.4.1.8.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
    - 4.4.1.8.2 Adult Market, 2021 - 2033 (USD Million)
  - 4.4.1.9 Others Market, 2021 - 2033 (USD Million)
    - 4.4.1.9.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
    - 4.4.1.9.2 Adult Market, 2021 - 2033 (USD Million)
4.5. Bacterial Vaccines
- 4.5.1 Bacterial Vaccine Market, 2021 - 2033 (USD Million)
  - 4.5.1.1 Meningococcal Diseases Market, 2021 - 2033 (USD Million)
  - 4.5.1.2 Pneumococcal diseases Market, 2021 - 2033 (USD Million)
  - 4.5.1.3 DPT Market, 2021 - 2033 (USD Million)
  - 4.5.1.4 Others Market, 2021 - 2033 (USD Million)
4.6. Cancer Vaccines
- 4.6.1 Cancer Vaccine Market, 2021 - 2033 (USD Million)
  - 4.6.1.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
  - 4.6.1.2 Adult Market, 2021 - 2033 (USD Million)
4.7. Allergy Vaccines
- 4.7.1 Allergy Vaccine Market, 2021 - 2033 (USD Million)
  - 4.7.1.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
  - 4.7.1.2 Adult Market, 2021 - 2033 (USD Million)
4.8. Other
- 4.8.1 Other Market, 2021 - 2033 (USD Million)
  - 4.8.1.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
  - 4.8.1.2 Adult Market, 2021 - 2033 (USD Million)

Chapter 5. Vaccine Market: Type Business Analysis

5.1. Type Market Share, 2025 & 2033
5.2. Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
5.4. Subunit Vaccines
- 5.4.1 Subunit Vaccine Market, 2021 - 2033 (USD Million)
  - 5.4.1.1 Recombinant Vaccine Market, 2021 - 2033 (USD Million)
  - 5.4.1.2 Conjugate Vaccine Market, 2021 - 2033 (USD Million)
  - 5.4.1.3 Toxoid Vaccine Market, 2021 - 2033 (USD Million)
5.5. Inactivated
- 5.5.1 Inactivated Market, 2021 - 2033 (USD Million)
5.6. Live Attenuated
- 5.6.1 Live Attenuated Market, 2021 - 2033 (USD Million)
5.7. mRNA Vaccines
- 5.7.1 mRNA Vaccine Market, 2021 - 2033 (USD Million)
5.8. Viral Vector Vaccines
- 5.8.1 Viral Vector Vaccine Market, 2021 - 2033 (USD Million)

Chapter 6. Vaccine Market: Route of Administration Business Analysis

6.1. Route of Administration Market Share, 2025 & 2033
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
6.4. Oral
- 6.4.1 Oral Market, 2021 - 2033 (USD Million)
6.5. Parenteral
- 6.5.1 Parenteral Market, 2021 - 2033 (USD Million)
6.6. Nasal
- 6.6.1 Nasal Market, 2021 - 2033 (USD Million)

Chapter 7. Vaccine Market: Age Group Business Analysis

7.1. Age Group Market Share, 2025 & 2033
7.2. Age Group Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Age Group, 2021 to 2033 (USD Million)
7.4. Pediatric
- 7.4.1 Pediatric Market, 2021 - 2033 (USD Million)
7.5. Adult
- 7.5.1 Adult Market, 2021 - 2033 (USD Million)

Chapter 8. Vaccine Market: Distribution Channel Business Analysis

8.1. Distribution Channel Market Share, 2025 & 2033
8.2. Distribution Channel Segment Dashboard
8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
8.4. Hospital & Retail Pharmacies
8.5. Government Suppliers
- 8.5.1 Government Suppliers Market, 2021 - 2033 (USD Million)
8.6. Others
- 8.6.1 Others Market, 2021 - 2033 (USD Million)

Chapter 9. Vaccine Market: Regional Estimates & Trend Analysis

9.1 Regional Market Share Analysis, 2025 & 2033
9.2 Regional Market Dashboard
9.3 Market Size & Forecasts Trend Analysis, 2021 to 2033:
9.4 North America
- 9.4.1 North America Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 9.4.2 U.S.
  - 9.4.2.1 Key Country Dynamics
  - 9.4.2.2 Regulatory Framework
  - 9.4.2.3 Pricing Analysis
  - 9.4.2.4 U.S. Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.3 Canada
  - 9.4.3.1 Key Country Dynamics
  - 9.4.3.2 Regulatory Framework
  - 9.4.3.3 Pricing Analysis
  - 9.4.3.4 Canada Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.4 Mexico
  - 9.4.4.1 Key Country Dynamics
  - 9.4.4.2 Regulatory Framework
  - 9.4.4.3 Pricing Analysis
  - 9.4.4.4 Mexico Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5 Europe
- 9.5.1 Europe Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 9.5.2 UK
  - 9.5.2.1 Key Country Dynamics
  - 9.5.2.2 Regulatory Framework
  - 9.5.2.3 Pricing Analysis
  - 9.5.2.4 UK Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.3 Germany
  - 9.5.3.1 Key Country Dynamics
  - 9.5.3.2 Regulatory Framework
  - 9.5.3.3 Pricing Analysis
  - 9.5.3.4 Germany Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.4 France
  - 9.5.4.1 Key Country Dynamics
  - 9.5.4.2 Regulatory Framework
  - 9.5.4.3 Pricing Analysis
  - 9.5.4.4 France Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.5 Italy
  - 9.5.5.1 Key Country Dynamics
  - 9.5.5.2 Regulatory Framework
  - 9.5.5.3 Pricing Analysis
  - 9.5.5.4 Italy Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.6 Spain
  - 9.5.6.1 Key Country Dynamics
  - 9.5.6.2 Regulatory Framework
  - 9.5.6.3 Pricing Analysis
  - 9.5.6.4 Spain Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.7 Denmark
  - 9.5.7.1 Key Country Dynamics
  - 9.5.7.2 Regulatory Framework
  - 9.5.7.3 Pricing Analysis
  - 9.5.7.4 Denmark Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.8 Norway
  - 9.5.8.1 Key Country Dynamics
  - 9.5.8.2 Regulatory Framework
  - 9.5.8.3 Pricing Analysis
  - 9.5.8.4 Norway Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.9 Sweden
  - 9.5.9.1 Key Country Dynamics
  - 9.5.9.2 Regulatory Framework
  - 9.5.9.3 Pricing Analysis
  - 9.5.9.4 Sweden Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6 Asia Pacific
- 9.6.1 Asia Pacific Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 9.6.2 Japan
  - 9.6.2.1 Key Country Dynamics
  - 9.6.2.2 Regulatory Framework
  - 9.6.2.3 Pricing Analysis
  - 9.6.2.4 Japan Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.3 China
  - 9.6.3.1 Key Country Dynamics
  - 9.6.3.2 Regulatory Framework
  - 9.6.3.3 Pricing Analysis
  - 9.6.3.4 China Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.4 India
  - 9.6.4.1 Key Country Dynamics
  - 9.6.4.2 Regulatory Framework
  - 9.6.4.3 Pricing Analysis
  - 9.6.4.4 India Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.5 South Korea
  - 9.6.5.1 Key Country Dynamics
  - 9.6.5.2 Regulatory Framework
  - 9.6.5.3 Pricing Analysis
  - 9.6.5.4 South Korea Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.6 Australia
  - 9.6.6.1 Key Country Dynamics
  - 9.6.6.2 Regulatory Framework
  - 9.6.6.3 Pricing Analysis
  - 9.6.6.4 Australia Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.7 Thailand
  - 9.6.7.1 Key Country Dynamics
  - 9.6.7.2 Regulatory Framework
  - 9.6.7.3 Pricing Analysis
  - 9.6.7.4 Thailand Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.7 Latin America
- 9.7.1 Latin America Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 9.7.2 Brazil
  - 9.7.2.1 Key Country Dynamics
  - 9.7.2.2 Regulatory Framework
  - 9.7.2.3 Pricing Analysis
  - 9.7.2.4 Brazil Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.3 Argentina
  - 9.7.3.1 Key Country Dynamics
  - 9.7.3.2 Regulatory Framework
  - 9.7.3.3 Pricing Analysis
  - 9.7.3.4 Argentina Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.8 Middle East & Africa
- 9.8.1 Middle East & Africa Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 9.8.2 South Africa
  - 9.8.2.1 Key Country Dynamics
  - 9.8.2.2 Regulatory Framework
  - 9.8.2.3 Pricing Analysis
  - 9.8.2.4 South Africa Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.8.3 Saudi Arabia
  - 9.8.3.1 Key Country Dynamics
  - 9.8.3.2 Regulatory Framework
  - 9.8.3.3 Pricing Analysis
  - 9.8.3.4 Saudi Arabia Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.8.4 UAE
  - 9.8.4.1 Key Country Dynamics
  - 9.8.4.2 Regulatory Framework
  - 9.8.4.3 Pricing Analysis
  - 9.8.4.4 UAE Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.8.5 Kuwait
  - 9.8.5.1 Key Country Dynamics
  - 9.8.5.2 Regulatory Framework
  - 9.8.5.3 Pricing Analysis
  - 9.8.5.4 Kuwait Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

10.1. Participant Overview
10.2. Company Market Position Analysis
10.3. Company Categorization
10.4. Strategy Mapping
10.5. Company Profiles/Listing
- 10.5.1 Serum Institute of India Pvt. Ltd.
  - 10.5.1.1 Overview
  - 10.5.1.2 Financial Performance
  - 10.5.1.3 Application Benchmarking
  - 10.5.1.4 Strategic Initiatives
- 10.5.2 Seqirus
  - 10.5.2.1 Overview
  - 10.5.2.2 Financial Performance
  - 10.5.2.3 Application Benchmarking
  - 10.5.2.4 Strategic Initiatives
- 10.5.3 Sanofi
  - 10.5.3.1 Overview
  - 10.5.3.2 Financial Performance
  - 10.5.3.3 Application Benchmarking
  - 10.5.3.4 Strategic Initiatives
- 10.5.4 Merck & Co., Inc.
  - 10.5.4.1 Overview
  - 10.5.4.2 Financial Performance
  - 10.5.4.3 Application Benchmarking
  - 10.5.4.4 Strategic Initiatives
- 10.5.5 Pfizer Inc.
  - 10.5.5.1 Overview
  - 10.5.5.2 Financial Performance
  - 10.5.5.3 Application Benchmarking
  - 10.5.5.4 Strategic Initiatives
- 10.5.6 Moderna Inc.
  - 10.5.6.1 Overview
  - 10.5.6.2 Financial Performance
  - 10.5.6.3 Application Benchmarking
  - 10.5.6.4 Strategic Initiatives
- 10.5.7 Sinovac
  - 10.5.7.1 Overview
  - 10.5.7.2 Financial Performance
  - 10.5.7.3 Application Benchmarking
  - 10.5.7.4 Strategic Initiatives
- 10.5.8 BioNTech SE
  - 10.5.8.1 Overview
  - 10.5.8.2 Financial Performance
  - 10.5.8.3 Application Benchmarking
  - 10.5.8.4 Strategic Initiatives
- 10.5.9 AstraZeneca
  - 10.5.9.1 Overview
  - 10.5.9.2 Financial Performance
  - 10.5.9.3 Application Benchmarking
  - 10.5.9.4 Strategic Initiatives

Product Code: 978-1-68038-990-6

List of Tables

Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global Vaccine Market, by Region, 2021 - 2033 (USD Million)
Table 4. Global Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 5. Global Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 6. Global Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 7. Global Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 8. Global Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 9. North America Vaccine Market, by Country, 2021 - 2033 (USD Million)
Table 10. North America Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 11. North America Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 12. North America Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 13. North America Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 14. North America Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 15. U.S. Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 16. U.S. Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 17. U.S. Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 18. U.S. Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 19. U.S. Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 20. Canada Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 21. Canada Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 22. Canada Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 23. Canada Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 24. Canada Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 25. Mexico Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 26. Mexico Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 27. Mexico Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 28. Mexico Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 29. Mexico Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 30. Europe Vaccine Market, by Country, 2021 - 2033 (USD Million)
Table 31. Europe Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 32. Europe Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 33. Europe Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 34. Europe Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 35. Europe Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 36. UK Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 37. UK Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 38. UK Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 39. UK Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 40. UK Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 41. Germany Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 42. Germany Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 43. Germany Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 44. Germany Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 45. Germany Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 46. France Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 47. France Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 48. France Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 49. France Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 50. France Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 51. Italy Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 52. Italy Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 53. Italy Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 54. Italy Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 55. Italy Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 56. Spain Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 57. Spain Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 58. Spain Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 59. Spain Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 60. Spain Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 61. Denmark Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 62. Denmark Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 63. Denmark Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 64. Denmark Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 65. Denmark Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 66. Norway Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 67. Norway Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 68. Norway Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 69. Norway Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 70. Norway Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 71. Sweden Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 72. Sweden Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 73. Sweden Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 74. Sweden Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 75. Sweden Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 76. Asia Pacific Vaccine Market, by Country, 2021 - 2033 (USD Million)
Table 77. Asia Pacific Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 78. Asia Pacific Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 79. Asia Pacific Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 80. Asia Pacific Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 81. Asia Pacific Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 82. Japan Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 83. Japan Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 84. Japan Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 85. Japan Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 86. Japan Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 87. China Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 88. China Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 89. China Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 90. China Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 91. China Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 92. India Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 93. India Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 94. India Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 95. India Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 96. India Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 97. South Korea Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 98. South Korea Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 99. South Korea Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 100. South Korea Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 101. South Korea Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 102. Australia Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 103. Australia Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 104. Australia Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 105. Australia Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 106. Australia Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 107. Thailand Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 108. Thailand Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 109. Thailand Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 110. Thailand Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 111. Thailand Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 112. Latin America Vaccine Market, by Country, 2021 - 2033 (USD Million)
Table 113. Latin America Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 114. Latin America Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 115. Latin America Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 116. Latin America Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 117. Latin America Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 118. Brazil Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 119. Brazil Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 120. Brazil Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 121. Brazil Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 122. Brazil Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 123. Argentina Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 124. Argentina Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 125. Argentina Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 126. Argentina Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 127. Argentina Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 128. Middle East & Africa Vaccine Market, by Country, 2021 - 2033 (USD Million)
Table 129. Middle East & Africa Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 130. Middle East & Africa Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 131. Middle East & Africa Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 132. Middle East & Africa Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 133. Middle East & Africa Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 134. South Africa Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 135. South Africa Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 136. South Africa Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 137. South Africa Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 138. South Africa Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 139. Saudi Arabia Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 140. Saudi Arabia Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 141. Saudi Arabia Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 142. Saudi Arabia Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 143. Saudi Arabia Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 144. UAE Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 145. UAE Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 146. UAE Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 147. UAE Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 148. UAE Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 149. Kuwait Vaccine Market, by Indication, 2021 - 2033 (USD Million)
Table 150. Kuwait Vaccine Market, by Type, 2021 - 2033 (USD Million)
Table 151. Kuwait Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
Table 152. Kuwait Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
Table 153. Kuwait Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Vaccine Market outlook
Fig. 14 Vaccine Market competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Vaccine Market driver impact
Fig. 20 Vaccine Market restraint impact
Fig. 21 Vaccine Market strategic initiatives analysis
Fig. 22 Vaccine Market Indication movement analysis
Fig. 23 Vaccine Market Indication outlook and key takeaways
Fig. 24 Viral Vaccine market estimates and forecast, 2021 - 2033
Fig. 25 Hepatitis market estimates and forecast, 2021 - 2033
Fig. 26 Influenza market estimates and forecast, 2021 - 2033
Fig. 27 HPV market estimates and forecast, 2021 - 2033
Fig. 28 MMR market estimates and forecast, 2021 - 2033
Fig. 29 Rotavirus market estimates and forecast, 2021 - 2033
Fig. 30 Herpes Zoster market estimates and forecast, 2021 - 2033
Fig. 31 Japanese Encephalitis market estimates and forecast, 2021 - 2033
Fig. 32 RSV market estimates and forecast, 2021 - 2033
Fig. 33 Others market estimates and forecasts, 2021 - 2033
Fig. 34 Bacterial Vaccine market estimates and forecast, 2021 - 2033
Fig. 35 Meningococcal Diseases market estimates and forecast, 2021 - 2033
Fig. 36 Pneumococcal diseases market estimates and forecast, 2021 - 2033
Fig. 37 DPT market estimates and forecast, 2021 - 2033
Fig. 38 Others market estimates and forecasts, 2021 - 2033
Fig. 39 Cancer Vaccine market estimates and forecast, 2021 - 2033
Fig. 40 Pediatric (Children) market estimates and forecast, 2021 - 2033
Fig. 41 Adult market estimates and forecast, 2021 - 2033
Fig. 42 Allergy Vaccine market estimates and forecast, 2021 - 2033
Fig. 43 Pediatric (Children) market estimates and forecast, 2021 - 2033
Fig. 44 Adult market estimates and forecast, 2021 - 2033
Fig. 45 Other market estimates and forecast, 2021 - 2033
Fig. 46 Pediatric (Children) market estimates and forecast, 2021 - 2033
Fig. 47 Adult market estimates and forecast, 2021 - 2033
Fig. 48 Vaccine Market Type movement analysis
Fig. 49 Vaccine Market Type outlook and key takeaways
Fig. 50 Subunit Vaccine market estimates and forecast, 2021 - 2033
Fig. 51 Recombinant Vaccine market estimates and forecast, 2021 - 2033
Fig. 52 Conjugate Vaccine market estimates and forecast, 2021 - 2033
Fig. 53 Toxoid Vaccine market estimates and forecast, 2021 - 2033
Fig. 54 Inactivated market estimates and forecasts, 2021 - 2033
Fig. 55 Live Attenuated market estimates and forecast, 2021 - 2033
Fig. 56 mRNA Vaccine market estimates and forecast, 2021 - 2033
Fig. 57 Viral Vector Vaccine market estimates and forecast, 2021 - 2033
Fig. 58 Vaccine Market Route of Administration movement analysis
Fig. 59 Vaccine Market Route of Administration outlook and key takeaways
Fig. 60 Oral market estimates and forecast, 2021 - 2033
Fig. 61 Parenteral market estimates and forecast, 2021 - 2033
Fig. 62 Nasal market estimates and forecast, 2021 - 2033
Fig. 63 Vaccine Market Age Group movement analysis
Fig. 64 Vaccine Market Age Group outlook and key takeaways
Fig. 65 Pediatric market estimates and forecast, 2021 - 2033
Fig. 66 Adult market estimates and forecast, 2021 - 2033
Fig. 67 Vaccine Market Distribution Channel movement analysis
Fig. 68 Vaccine Market Distribution Channel outlook and key takeaways
Fig. 69 Hospital & Retail Pharmacies market estimates and forecast, 2021 - 2033
Fig. 70 Government Suppliers market estimates and forecast, 2021 - 2033
Fig. 71 Others market estimates and forecasts, 2021 - 2033
Fig. 72 Vaccine Market Regional movement analysis
Fig. 73 Vaccine Market Regional outlook and key takeaways
Fig. 74 Vaccine Market share and leading players
Fig. 75 North America Vaccine Market share and leading players
Fig. 76 Europe Vaccine Market share and leading players
Fig. 77 Asia Pacific Vaccine Market share and leading players
Fig. 78 Latin America Vaccine Market share and leading players
Fig. 79 Middle East & Africa Vaccine Market share and leading players
Fig. 80 North America Vaccine Market SWOT Analysis
Fig. 81 Europe Vaccine Market SWOT Analysis
Fig. 82 Asia Pacific Vaccine Market SWOT Analysis
Fig. 83 Latin America Vaccine Market SWOT Analysis
Fig. 84 Middle East & Africa Vaccine Market SWOT Analysis
Fig. 85 North America Vaccine Market Analysis, by country
Fig. 86 North America
Fig. 87 North America Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 88 US
Fig. 89 US Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 90 Canada
Fig. 91 Canada Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 92 Mexico
Fig. 93 Mexico Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 94 Europe
Fig. 95 Europe Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 96 UK
Fig. 97 UK Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 98 Germany
Fig. 99 Germany Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 100 France
Fig. 101 France Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 102 Italy
Fig. 103 Italy Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 104 Spain
Fig. 105 Spain Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 106 Denmark
Fig. 107 Denmark Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 108 Sweden
Fig. 109 Sweden Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 110 Norway
Fig. 111 Norway Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 112 Asia Pacific
Fig. 113 Asia Pacific Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 114 China
Fig. 115 China Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 116 Japan
Fig. 117 Japan Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 118 India
Fig. 119 India Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 120 Thailand
Fig. 121 Thailand Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 122 South Korea
Fig. 123 South Korea Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 124 Australia
Fig. 125 Australia Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 126 Latin America
Fig. 127 Latin America Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 128 Brazil
Fig. 129 Brazil Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 130 Argentina
Fig. 131 Argentina Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 132 Middle East & Africa
Fig. 133 Middle East & Africa Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 134 South Africa
Fig. 135 South Africa Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 136 Saudi Arabia
Fig. 137 Saudi Arabia Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 138 UAE
Fig. 139 UAE Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 140 Kuwait
Fig. 141 Kuwait Vaccine Market Estimates and Forecasts 2021 - 2033
Fig. 142 Market share of key market players - Vaccine Market

Vaccine Market Size, Share & Trends Analysis Report By Indication, By Type, By Route Of Administration, By Age Group, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033

Description

Table of Contents

List of Tables

Vaccine Market Summary

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Vaccine Market Variables, Trends, & Scope

Chapter 4. Vaccine Market: Indication Business Analysis

Chapter 5. Vaccine Market: Type Business Analysis

Chapter 6. Vaccine Market: Route of Administration Business Analysis

Chapter 7. Vaccine Market: Age Group Business Analysis

Chapter 8. Vaccine Market: Distribution Channel Business Analysis

Chapter 9. Vaccine Market: Regional Estimates & Trend Analysis

Chapter 10. Competitive Landscape

List of Tables

List of Figures